A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), Phase 1b, open-label, dose-escalation, safety trial
consisting of 3 dose levels. Subjects will always be treated in cohorts of size 3, with from
3 up to 6 cohorts i.e. 9-18 subjects.